Civatech Oncology Stock
Civatech Oncology is a medical device company that develops polymer-based devices to treat cancer using localized low-dose-rate radiation.
Sign up today and learn more about Civatech Oncology Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Civatech Oncology Stock
Civatech Oncology is a medical device company that develops polymer-based devices to treat cancer using localized low-dose-rate radiation. Because polymers are easy to manufacture in different shapes and formats, CivaTech's patented and patent-pending technology enables devices that can be designed and fabricated for specific tumor types. Its first product, the CivaString, has been granted FDA 510k clearance to treat any solid tumor. The company was founded in 2006 and is based in Durham, North Carolina, United States.
Funding History
| June 2009 | $100K |
|---|---|
| November 2009 | $2K |
| March 2010 | $115K |
| December 2010 | $700K |
| April 2013 | $700K |
| June 2013 | $400K |
| April 2014 | $320K |
| July 2014 | $1.5M |
| April 2016 | $1.6M |
| September 2016 | $2.7M |
| August 2017 | $916K |
| December 2017 | $15K |
Management
Co-Founder & Executive Chairman
Suzanne Troxler Babcock
Attorney-in-fact
Merrill M. Mason
Press
biospace - Jun, 29 2022
CivaTech Oncology selected to present at BIO International Conferencewraltechwire - Nov, 23 2021
Morrisville’s CivaTech Oncology raises more than $7.9M and could raise morebusinesswire - Oct, 1 2019
CivaDerm™ - CivaTech Oncology’s New Skin Cancer Therapy Product Receives FDA Clearancewraltechwire - Jan, 22 2017
NC Biotech Center-backed companies raise $11M to close 2016EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
